TY  - JOUR
EP  - 2575
AV  - public
Y1  - 2021/12/30/
TI  - Chlorthalidone in Advanced Chronic Kidney Disease - Have We Missed a Trick?
PB  - MASSACHUSETTS MEDICAL SOC
ID  - discovery10141835
N2  - Control of hypertension is central to the management of chronic kidney disease, both to preserve residual kidney function and to reduce the associated high risk of cardiovascular events. International guidelines recently updated by the Kidney Disease: Improving Global Outcomes Organization recommend that patients with chronic kidney disease and hypertension be treated to reduce standardized office systolic blood pressure to less than 120 mm Hg, unless there are obvious reasons not to do so. This ambitious target is difficult to achieve with currently available antihypertensive medications, particularly in patients with more advanced chronic kidney disease (stages 4 and 5)
SP  - 2574
VL  - 385
N1  - This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions.
IS  - 27
SN  - 1533-4406
UR  - https://doi.org/10.1056/NEJMe2118149
A1  - Wheeler, DC
JF  - New England Journal of Medicine
ER  -